Abbott Laboratories [NYSE: ABT] surged by $0.13 during the normal trading session on Thursday and reaching a high of $133.37 during the day while it closed the day at $132.41.
Abbott Laboratories stock has also loss -2.12% of its value over the past 7 days. However, ABT stock has inclined by 3.92% in the 3 months of the year. Over the past six months meanwhile, it has gained 16.78% and gained 17.06% year-on date.
The market cap for ABT stock reached $230.37 billion, with 1.74 billion shares outstanding and 1.73 billion shares in the current float. Compared to the average trading volume of 6.69M shares, ABT reached a trading volume of 4935702 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $142.61 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.97. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on June 16, 2025. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on October 08, 2024, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $131, while Piper Sandler analysts kept a Overweight rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.31, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 5.44. The Price to Book ratio for the last quarter was 4.72, with the Price to Cash per share for the same quarter was set at 3.93. Price to Free Cash Flow for ABT in the course of the last twelve months was 34.61 with Quick ratio for the last quarter at 1.27.
ABT stock trade performance evaluation
Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.12. With this latest performance, ABT shares dropped by -2.32% in over the last four-week period, additionally plugging by 16.78% over the last 6 months – not to mention a rise of 27.71% in the past year of trading.
Abbott Laboratories [ABT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of 16.96% and a Gross Margin at 51.42%. Abbott Laboratories’s Net Margin is presently recorded at 31.72%.
Return on Equity for this stock inclined to 17.45%, with Return on Assets sitting at 17.45%.
Earnings per share (EPS) analysis for Abbott Laboratories [ABT] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 10.36%.
Abbott Laboratories [ABT]: Institutional Ownership
There are presently around $80.53%, or 80.97%% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 166.35 million shares, which is approximately 9.5932%. BLACKROCK INC., holding 131.13 million shares of the stock with an approximate value of $$13.63 billion in ABT stocks shares; and BLACKROCK INC., currently with $$7.73 billion in ABT stock with ownership which is approximately 4.2903%.
